Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunvozertinib in advanced NSCLC with EGFR or HER2 mutation
NCT03974022Phase 2Active, not recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jul 2019
- Primary completion
- Jul 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
A Phase 2 trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Jul 2019; status: active, not recruiting.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03974022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03974022.